Unleashing the Potential of Gene Therapies: Overcoming HTA Challenges

By Staff Writer

October 16, 2023

The Promise and Challenges of Gene Therapies

Gene therapies offer transformational benefits to patients, health systems, and society. However, several challenges hinder timely patient access. A report commissioned by Pfizer, penned by Besley et al. (2022), discusses the difficulties of health technology assessment (HTA) of gene therapies and proposes potential solutions.

 



Gene therapies, as defined by the European Medicines Agency (EMA), are medicines containing genes that lead to therapeutic, prophylactic, or diagnostic effects. They work by inserting ‘recombinant’ genes into the body to treat a variety of diseases, including genetic disorders, cancer, or long-term diseases.

Recommendations for Overcoming HTA Challenges

Based on a review of the literature and insights from an international panel of HTA and health economics experts, the authors propose six overarching recommendations. These recommendations aim to address the challenges in fully capturing the potential value of gene therapies as part of the HTA process and to improve the quality and acceptability of the evidence generated.

 


The recommendations are not specific to gene therapies and should be consistently applied across HTA of other treatments. However, due to the unique challenges presented by the HTA of gene therapies, if implemented, these recommendations are likely to have a larger impact on the assessment of gene therapies.

The report also assesses the extent to which these recommendations are being achieved in selected European countries, Australia, and Canada. It reviews the HTA outcomes of key gene therapies conducted in these countries to provide further understanding of the current state of play.

 

Reference url

Recent Posts

Navigating Challenges for Small Countries to Access Innovative Medicines

By João L. Carapinha

July 31, 2025

Access to innovative medicines is a pressing issue for patients in smaller European countries. These nations often face significant barriers in obtaining timely and equitable healthcare solutions. The article "Ensuring access to innovative medicines for patients in smaller countries" (linked belo...
Mental Health Policy Integration: A Cross-Sector Imperative for Well-being and Productivity
The purpose of this update is to review a recent Lancet editorial (linked below) on mental health policy integration in public policy frameworks. The article “Mental health in all policies” emphasizes that mental health influences individual well-being, societal cohesion, and economic productivit...
Novartis Gains Approval for Groundbreaking Malaria Treatment for Infants

By Rene Pretorius

July 30, 2025

In this article we review Swissmedic's approval of Novartis' Coartem Baby. It is the first malaria treatment for infants under 4.5 kilograms. This novel formulation addresses a critical gap in antimalarial care. Existing treatments were unsuitable due to dosing and metabolism concerns in young in...